Sagimet Stock Surges as $175 Million Raise Sharpens Acne Drug Push
Sagimet Biosciences priced 29.17 million shares at $6 each, seeking to raise $175 million to fund a U.S. Phase 3 acne trial for denifanstat. Shares rose 38% to $8.12 on heavy volume Monday. The company will delay further work on its MASH liver-disease program unless it secures non-dilutive funding. Sagimet reported about $104.5 million in cash and equivalents.